Amgen shared a post on X:
“Heading into 2026: Amgen bolsters its oncology pipeline.
Amgen will acquire UK-based Dark Blue Therapeutics Ltd. adding an investigational small molecule to treat acute myeloid leukemia (AML).
This builds on our commitment to patients with difficult to treat cancers.
Acquisition Details.”
More posts about Amgen.